Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Journal of Cutaneous Pathology
|
August 24, 2005
The diagnostic concordance of actinic keratosis and squamous cell carcinoma
Daniel A Davis, John P Donahue, James E Bost, et al.
Journal of Pharmaceutical Sciences
|
November 23, 2020
Selective Laser Sintering 3-Dimensional Printing as a Single Step Process to Prepare Amorphous Solid Dispersion Dosage Forms for Improved Solubility and Dissolution Rate
Daniel A Davis, Rishi Thakkar, Yongchao Su, et al.
Dermatology Online Journal
|
May 2, 2022
Curettage of skin cancer-the bruised apple analogy
Kevin Shi, Derek Davis, Daniel A Davis, et al.
AAPS Pharmscitech
|
November 8, 2020
Innovations in Thermal Processing: Hot-Melt Extrusion and KinetiSol® Dispersing
Deck Khong Tan, Daniel A Davis, Dave A Miller, et al.
AAPS Pharmscitech
|
June 21, 2023
Can the Oral Bioavailability of the Discontinued Prostate Cancer Drug Galeterone Be Improved by Processing Method? KinetiSol® Outperforms Spray Drying in a Head-to-head Comparison
Stephen A Thompson, Urvi Gala, Daniel A Davis, et al.
Biomedicines
|
May 27, 2023
Pre-Processing a Polymer Blend into a Polymer Alloy by KinetiSol Enables Increased Ivacaftor Amorphous Solid Dispersion Drug Loading and Dissolution
Stephen A Thompson, Daniel A Davis, Dave A Miller, et al.
International Journal of Pharmaceutics
|
May 26, 2026
Evaluation of powder discharge-based KinetiSol<sup>TM</sup> (pKSD) as a fast and solvent-free particle engineering process for pulmonary drug delivery
Beatriz Behrend-Keim, Miguel O Jara, Daniel A Davis, et al.
Clinical Therapeutics
|
October 9, 2008
Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement
Mary Jayne Kennedy, Daniel A Davis, Ned Smith, et al.
International Journal of Pharmaceutics: X
|
January 3, 2022
Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity
Daniel A Davis, Dave A Miller, Supawan Santitewagun, et al.
Molecular Pharmaceutics
|
February 28, 2018
Personalized Medicine in Nasal Delivery: The Use of Patient-Specific Administration Parameters To Improve Nasal Drug Targeting Using 3D-Printed Nasal Replica Casts
Zachary N Warnken, Hugh D C Smyth, Daniel A Davis, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Journal of Cutaneous Pathology
|
August 24, 2005
The diagnostic concordance of actinic keratosis and squamous cell carcinoma
Daniel A Davis, John P Donahue, James E Bost, et al.
Journal of Pharmaceutical Sciences
|
November 23, 2020
Selective Laser Sintering 3-Dimensional Printing as a Single Step Process to Prepare Amorphous Solid Dispersion Dosage Forms for Improved Solubility and Dissolution Rate
Daniel A Davis, Rishi Thakkar, Yongchao Su, et al.
Dermatology Online Journal
|
May 2, 2022
Curettage of skin cancer-the bruised apple analogy
Kevin Shi, Derek Davis, Daniel A Davis, et al.
AAPS Pharmscitech
|
November 8, 2020
Innovations in Thermal Processing: Hot-Melt Extrusion and KinetiSol® Dispersing
Deck Khong Tan, Daniel A Davis, Dave A Miller, et al.
AAPS Pharmscitech
|
June 21, 2023
Can the Oral Bioavailability of the Discontinued Prostate Cancer Drug Galeterone Be Improved by Processing Method? KinetiSol® Outperforms Spray Drying in a Head-to-head Comparison
Stephen A Thompson, Urvi Gala, Daniel A Davis, et al.
Biomedicines
|
May 27, 2023
Pre-Processing a Polymer Blend into a Polymer Alloy by KinetiSol Enables Increased Ivacaftor Amorphous Solid Dispersion Drug Loading and Dissolution
Stephen A Thompson, Daniel A Davis, Dave A Miller, et al.
International Journal of Pharmaceutics
|
May 26, 2026
Evaluation of powder discharge-based KinetiSol<sup>TM</sup> (pKSD) as a fast and solvent-free particle engineering process for pulmonary drug delivery
Beatriz Behrend-Keim, Miguel O Jara, Daniel A Davis, et al.
Clinical Therapeutics
|
October 9, 2008
Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement
Mary Jayne Kennedy, Daniel A Davis, Ned Smith, et al.
International Journal of Pharmaceutics: X
|
January 3, 2022
Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity
Daniel A Davis, Dave A Miller, Supawan Santitewagun, et al.
Molecular Pharmaceutics
|
February 28, 2018
Personalized Medicine in Nasal Delivery: The Use of Patient-Specific Administration Parameters To Improve Nasal Drug Targeting Using 3D-Printed Nasal Replica Casts
Zachary N Warnken, Hugh D C Smyth, Daniel A Davis, et al.
Page
of 3